Sugi Predict

Sugi Predict / Targets / AZI2

AZI2

5-azacytidine-induced protein 2 · Q9H6S1 · AZI2 on Sugi Atlas →

273 patent compounds predicted against AZI2, 260 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1554482 SCHEMBL1554482 1.00 1/20
SCHEMBL1546914 SCHEMBL1546914 0.89 1/20
SCHEMBL1547091 SCHEMBL1547091 0.88 1/20
SCHEMBL1555902 SCHEMBL1555902 0.88 1/20
SCHEMBL1547102 SCHEMBL1547102 0.86 1/20
SCHEMBL1591314 SCHEMBL1591314 0.85 1/20
SCHEMBL1554516 SCHEMBL1554516 0.84 1/20
SCHEMBL19061011 SCHEMBL19061011 0.83 1/20
SCHEMBL1546814 SCHEMBL1546814 0.83 1/20
SCHEMBL12709130 SCHEMBL12709130 0.81 1/20
SCHEMBL1546619 SCHEMBL1546619 0.80 1/20
SCHEMBL1547123 SCHEMBL1547123 0.80 1/20
SCHEMBL1546581 SCHEMBL1546581 0.80 1/20
SCHEMBL1555938 SCHEMBL1555938 0.80 1/20
SCHEMBL1546971 SCHEMBL1546971 0.79 1/20
SCHEMBL1555731 SCHEMBL1555731 0.79 1/20
SCHEMBL19060383 SCHEMBL19060383 0.79 1/20
SCHEMBL1547095 SCHEMBL1547095 0.79 1/20
SCHEMBL1591660 SCHEMBL1591660 0.79 1/20
SCHEMBL1547383 SCHEMBL1547383 0.78 1/20

Clinical trials — most relevant to AZI2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC PHASE3UNKNOWN
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR PHASE3NOT_YET_RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML PHASE2UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) PHASE2COMPLETED
Decitabine in Treating Patients With Myelofibrosis PHASE2ACTIVE_NOT_RECRUITING
Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy PHASE2COMPLETED
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 PHASE2COMPLETED
VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation PHASE2UNKNOWN
Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation PHASE2COMPLETED
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS PHASE1/PHASE2COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer PHASE1COMPLETED
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) PHASE1COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML PHASE1COMPLETED
PRO#0118: Decitabine Plus Mini Flu-Bu PHASE1COMPLETED
Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy PHASE1ENROLLING_BY_INVITATION
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a AZI2 binder may also engage these)

ProteinNameSimilarity
Q4R3X1 — 1.000 Q4R3X1 →
Q5RD40 — 1.000 Q5RD40 →
Q3SYW5 — 1.000 Q3SYW5 →
Q9QYP6 — 0.993 Q9QYP6 →
Q4KMA0 — 0.989 Q4KMA0 →
P97817 — 0.988 P97817 →
Q86Z20 — 0.985 Q86Z20 →
Q5U465 — 0.983 Q5U465 →
CDR2 Cerebellar degeneration-related protein 2 0.982 landscape →
Q5ZJA3 — 0.982 Q5ZJA3 →
Q96G01 — 0.981 Q96G01 →
P49140 — 0.981 P49140 →
Q8NA72 — 0.981 Q8NA72 →
Q3URD3 — 0.980 Q3URD3 →
Q6ZUS6 — 0.980 Q6ZUS6 →
Q17QT2 — 0.978 Q17QT2 →
Q4R8G4 — 0.978 Q4R8G4 →
Q9H2G9 — 0.978 Q9H2G9 →
P0C219 — 0.978 P0C219 →
A0PJP4 — 0.978 A0PJP4 →
E9PVD1 — 0.978 E9PVD1 →
Q6DH86 — 0.977 Q6DH86 →
Q9NUQ3 — 0.977 Q9NUQ3 →
Q501R9 — 0.976 Q501R9 →
Q6NRH3 — 0.976 Q6NRH3 →
P97432 — 0.976 P97432 →
P0C6S7 — 0.976 P0C6S7 →
Q5R4U3 — 0.976 Q5R4U3 →
Q17QG3 — 0.976 Q17QG3 →
Q5T7V8 — 0.975 Q5T7V8 →